Lunning and Kamdar Debate the Role of Pola-R-CHP in Treatment-Naïve DLBCL

Author(s):

Dr Lunning sits down with Kamdar to discuss the design of the POLARIX trial, the ways in which its results have changed their practice when treating patients with DLBCL, and the importance of further research investigating the molecular heterogeneity of DLBCL to determine potential causes of early relapse with pola-R-CHP.

The Blood Club, hosted by Matthew Lunning, DO, FACP, is a podcast that seeks to translate the latest hematologic oncology research findings into practical clinical implications for the treatment of patients with hematologic malignancies. Dr Lunning is an associate professor in the Division of Oncology & Hematology, associate vice chair of research in the Department of Internal Medicine, and assistant vice chancellor of clinical research at the University of Nebraska Medical Center in Omaha.

In this episode, Dr Lunning sits down with Manali Kamdar, MD, to discuss the potentially practice-informing or practice-changing findings from the phase 3 POLARIX trial (NCT03274492) of pola-R-CHP (rituximab [Rituxan], cyclophosphamide, doxorubicin, polatuzumab vedotin-piiq [Polivy], and prednisone) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL). Dr Kamdar is the clinical director of Lymphoma Services at the UCHealth Blood Disorders and Cell Therapies Center – Anschutz Medical Campus at the University of Colorado in Aurora.

Drs Lunning and Kamdar spotlight the design of the POLARIX trial, the ways in which its results have changed their practice when treating patients with DLBCL, and the importance of further research investigating the molecular heterogeneity of this disease to determine potential causes of early relapse with pola-R-CHP.